A comparative study of the renoprotective effects of benidipine and valsartan in primary hypertensive patients with proteinuria

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 12, 2009, Pages 647-650

  Tao, Peng ^a   Zhao, Hu ^a   Qing, Xia ^a   Bei, Jiang ^a   Xianhua, Li ^a   Xiangdong, Yang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Benidipine; CAS 105979 17 7; CAS 137862 53 4; Primary hypertension; Renoprotection; Valsartan

Indexed keywords

BENIDIPINE; VALSARTAN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION;

EID: 74249119713     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296454     Document Type: Article

References (24)

1. Matsuzaki G, Ishizaka N, Furuta K, Hongo M, Saito K, Sakurai R, et al. Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome. Eur J Pharmacol. 2008 Jun;587 (1-3):237-242.
2. Takayama M, Arakawa E, Yao K, Ina Y, Sato H, Hawegawa K, et al. Effects of combination of angiotensin receptor blocker and calcium channel blocker on ox-LDL levels and cardiovascular dysfunction in Dahl rats. Pharmacology. 2006;77(4):179-187.
3. Shikata C, Sekikawa T, Kimura N, Kojima A, Seki S, Oka H, et al. Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension. Exp Clin Cardol. 2007;12(1):33-36.
4. The Joint National Committee on Prevevtion, Detection, Evaluation and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevevtion, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-46
5. Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. European Society of Hypertension; European Society of Cardiology. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007;16(3):135-232.
6. Liu Lisheng. Guidelines for the management of hypertension in china. Clin J Hypertension. 2005 Feb;12 (Suppl.):9-10.
7. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatintine: A new prediction. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar;130(2):461-70.
8. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Diseases: Evaluation, Classification and Stratification. Am J Kidney Dis. 2002 Feb;39(2 suppl 1):S1-S266.
9. Keane W, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PAPADE): A position paper of the National Kidney Foundation. Am J Kidney Dis. 1999 May;33(5):1004-10.
10. Uzu T, Nishimura M, Fujii T, Sakaguchi M, Kanasaki M, Isshiki K, et al. Benidipine attenuates glomerular hypertension and reduces albuminuria in patients with metabolic syndrome. Hypertens Res. 2007 Feb;30(2):161-5.
11. 2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol. 2008 Apr;584 (2-3):424-34.
12. Seino H, Miyaguchi S, Yamazaki T, Ota S, Yabe R, Suzuki S. Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus. Analysis after switching from cilnidipine to benidipine. Arzneimittelforschung. 2007;57(8):526-31.
13. Saito F, Fujita H, Takahashi A, Ichiyama I, Harasawa S, Oiwa K, et al. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria. Hypertens Res. 2007 Jan;30(1):39-47.
14. 2+ channels in renal microcirculation. J Pharmacol Sci. 2005 Nov;99(3):221-7.
15. Gotoh Y, Mruaki K, Imaizumi Y. Effects of benidipine, a 1,4-dihydropyridine derivative, on single L-type Ca channel currents in vascular smooth muscle. Clin Prep. 1992;26:3879-901.
16. Shimada S, Nakajima Y, Yamamaoto K, Sawada Y, Iga T. Comparative pharmacodynamics of eight calciumchannel blocking agents in Japanese essential hypertensive patients. Biol PharmBull. 1996 Mar;19(3):430-7.
17. Tsuda K. Electron paramagnetic resonance investigation on modulatory effect of benidipine on membrane fluidity of erythrocytes in essential hypertension. Heart Vessels. 2008 Mar;23(2):134-9.
18. Suzuki K, Imada T, Gao F, Ma H, Nagata T. Radioautographic study of benidipine hydrochloride. Localization in the mesenteric artery of spontaneously hypertensive rat. Arzneimittelforschung. 1994 Feb;44(2):129-33.
19. Morikawa T, OkumuraM, Konishi Y, Okada N, Imanishhi M. Effects of benidipine on glomerular hemohynamics and proteinuria in patients with nondiabetic nephropathy. Hypertens Res. 2002;25:571-6.
20. Kimrua K. Effects of benidipine hydrochloride on renal arterioles. Ther Res. 1994;15:2237-40.
21. Gashti CN, Bakris GL. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2004 Mar;13(2):155-61.
22. Inoue S, Tomino Y. Effcets of calciumantagonists in hypertensive patients with renal dyfunction: A protective, randomized, parallel trial comparing benidipine and nifedipine. Nephrology (Carlton). 2004 Oct;9(5):265-71.
23. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New Engl J Med. 2001 Sep 20;345(12):870-8.
24. Croom KF, Curran MP, Goa KL, Perry CM. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs. 2004;64(9):999-1028.